Trabectedin: an anticancer drug from the sea

Bibliography

• ADIS R&D profile. Trabectedin. Drugs RD 2003;4:75-81
   Google Scholar
• Martinez EJ, Corey EJ. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents. Org Lett 2000;2:993-6
   PubMedGoogle Scholar
• Rinehart KL, Holt TG, Fregeau NL, Ecteinascidins 729, 743, 745, 759A, and 770: potent antitumor agents from the caribbean tunicate ecteinascidia turbinate. J Org Chem 1990;55:4515-16
   Google Scholar
• Pommier Y, Kohlhagen G, Bailly C, DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate ecteinascidia turbinate. Biochemistry 1996;35:13303-9
   PubMed Web of Science ®Google Scholar
• ADIS R&D profile. Trabectedin. Drugs RD 2006;7:317-28
   Google Scholar
• Izbicka E, Lawrence R, Raymond E, In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998;9:981-7
   PubMed Web of Science ®Google Scholar
• Twelves C, Hoekman K, Bowman A, Phase I and pharmacokinetics study of yondelis (Ecteinascidin-743: ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003;39:1842-51
   PubMed Web of Science ®Google Scholar
• Forouzesh B, Hidalgo M, Chu Q, Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res 2009;15:3591-9
   PubMed Web of Science ®Google Scholar
• Taamma A, Misset J, Riofrio M, Phase I and pharmacokinetic study of Ecteinascidin-743, a new marine compound, administered as a 24 hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-65
   PubMed Web of Science ®Google Scholar
• Puchalski TA, Ryan DP, Garcia-Carbonero R, Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variable and toxicity. Cancer Chemother Pharmacol 2002;50:309-19
   PubMed Web of Science ®Google Scholar
• Ryan DP, Supko JG, Eder JP, Phase I and pharmacokinetic study of ecteiniscidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-42
   PubMed Web of Science ®Google Scholar
• Beumer JH, Schellens JHM, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol Res 2005;51:391-8
   PubMed Web of Science ®Google Scholar
• Villalona-Calero MA, Eckhardt G, Weiss G, A phase I and pharmacokinetic study of Ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res 2002;8:75-85
   PubMed Web of Science ®Google Scholar
• Sessa C, Perotti A, Noberasco C, Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009;45:1153-61
   PubMed Web of Science ®Google Scholar
• Blay JY, von Mehren M, Samuels BL, Phase I combinatioin study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008;14:6656-62
   PubMed Web of Science ®Google Scholar
• Von Mehren M, Schilder RJ, Cheng JD, A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008;19:1802-9
   PubMed Web of Science ®Google Scholar
• Sessa C, Cresta S, Noberasco C, Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumors. Eur J Cancer 2009; doi:10.1016/j.ejca.2009.04.002
   Web of Science ®Google Scholar
• Messersmith WA, Jimeno A, Ettinger D, Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008;63:181-8
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Van Oosterom A, Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol 2005;23:576-84
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD, Efficacy of trabectedin (Ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602
   PubMed Web of Science ®Google Scholar
• Patel SR, Burgess MA, Plager C, Myxoid liposarcoma: experience with chemotherapy. Cancer 1994;74:1265-9
   PubMed Web of Science ®Google Scholar
• Gronchi A, Le Cesne A, Bui NB, A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL). J Clin Oncol 2009;27(Suppl 15):542
   PubMedGoogle Scholar
• Grosso F, Forni C, Frapolli R, Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. J Clin Oncol 2007;25(Suppl 18):10000
   Google Scholar
• Schoffski P, Casali PG, Taron M, DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). J Clin Oncol 2006;24(Suppl 18):9522
   Google Scholar
• Morgan JA, Le Cesne A, Chawla S, Randomized phase II study of trabectedin in patients with liposarcoma and Leiomyosarcoma (L-sarcoma) after failure of prior anthracyclines (A) and ifosfamide (I). J Clin Oncol 2007;25(Suppl 18):10060
   Google Scholar
• Demetri GD, Schuetze S, Blay J, Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma oe leiomyosarcoma after failure of prior anthracycline and ifosfamide. J Clin Oncol 2009;27(Suppl 15):10509
   Google Scholar
• Krasner CN, McMeekin DS, Chan S, A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;97:1618-24
   PubMed Web of Science ®Google Scholar
• Sessa C, De Braud F, Perotti A, Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fail. J Clin Oncol 2005;23:1867-74
   PubMed Web of Science ®Google Scholar
• Del Campo J, Roszak A, Ciuleanu T, Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J Clin Oncol 2006;24(Suppl 18):5031
   Google Scholar
• Zelek L, Yovine A, Brain E, A phase II study of yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006;94:1610-14
   PubMed Web of Science ®Google Scholar
• Gurtler JS, Goldstein L, Delprete S, Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol 2005;23(Suppl 16):625
   Google Scholar
• Michaelson MD, Gilligan T, Oh W, Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol 2005;23(Suppl 16):4517
   Google Scholar
• Monk B, Herzog T, Kaye S, A randomized phase III study of trabectedin with pegylated liposomal doxorubicin versus PLD in relapsed, recurrent ovarian cancer. Eur J Cancer 2008;16:ESMO-LBA4
   Google Scholar
• Moneo V, Serelde BG, Fominaya J, Extreme sensitivity to yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007;100:339-48
   PubMed Web of Science ®Google Scholar
• Manara MC, Perdichizzi S, Serra M, The molecular mechanisms responsible for resistance to ET-743 (trabectedin; yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 2005;27:1605-16
   PubMedGoogle Scholar
• Ryan DP, Puchalski T, Supko JG, A Phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002;7:531-8
   PubMed Web of Science ®Google Scholar
• Delaloge S, Yovine A, Taamma A, Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001;19:1248-55
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY, Phase II study of Ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-9
   PubMed Web of Science ®Google Scholar
• Huygh G, Clement PM, Dumez H, Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006; doi: 10.1155/SRCM/2006/562
   PubMedGoogle Scholar